Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
PEXEVA (paroxetine mesylate) is an oral selective serotonin reuptake inhibitor (SSRI) approved in 2003 for the treatment of depression, anxiety disorders, and related conditions. It works by increasing serotonin availability in the central nervous system to alleviate mood and anxiety symptoms. The mesylate salt formulation was developed to improve bioavailability and patient tolerability compared to earlier paroxetine formulations.
This product is in decline with minimal commercial infrastructure, indicating reduced hiring and focus on managed care or specialty roles rather than growth-oriented positions.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PEXEVA offers limited career advancement potential due to the product's LOE-approaching lifecycle and minimal market presence (0 linked jobs). Roles tend to focus on defending market share, managing payer relationships, and optimizing formulary placement rather than launch excitement or growth initiatives.
Worked on PEXEVA at Bel Air Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo